- Record: found
- Abstract: not found
- Article: not found
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Arnaud Scherpereel ,
Julien Mazieres ,
Laurent Greillier ,
Sylvie Lantuejoul ,
Pascal Dô ,
Olivier Bylicki ,
Isabelle Monnet ,
Romain Corre ,
Clarisse Audigier-Valette ,
Myriam Locatelli-Sanchez ,
Olivier Molinier ,
Florian Guisier ,
Thierry Urban ,
Catherine Ligeza-Poisson ,
David Planchard ,
Elodie Amour ,
Franck Morin ,
Denis Moro-Sibilot ,
Gérard Zalcman ,
Didier DEBIEUVRE ,
Sandrine HIRET ,
Jacques CADRANEL ,
Séverine FRABOULET-MOREAU ,
Delphine CARMIER
February 2019
February 2019
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d5049936e339">There is no recommended therapy for malignant pleural
mesothelioma that has progressed
after first-line pemetrexed and platinum-based chemotherapy. Disease control has been
less than 30% in all previous studies of second-line drugs. Preliminary results have
suggested that anti-programmed cell death 1 (PD-1) monoclonal antibody could be efficacious
in these patients. We thus aimed to prospectively assess the anti-PD-1 monoclonal
antibody alone or in combination with anti-cytotoxic T-lymphocyte protein 4 (CTLA-4)
antibody in patients with malignant pleural mesothelioma.
</p>